Commercially proven - Scalable by design - Trusted worldwide
The power behind commercial CGT
Commercially proven
We bring decades of experience, proven technology, a global presence, and a commitment to quality and speed.
Approved engineered T cell therapies* are manufactured using Miltenyi Biotec's solutions
Active clinical trials worldwide** are carried out using CliniMACS® Instruments
IND/IDE filings actively progressing with the FDA*** driven by Miltenyi Biotec solutions powering the next wave of CGT breakthroughs
* Approved cell therapies and gene-modified cell therapies in EU and USA, excluding minimally manipulated cell therapies, cord blood products, and tissue-engineered therapies.
** Active clinical trials, hospital treatments, or commercial treatments using CliniMACS® Instruments for manufacturing of cell products.
*** ~ Number of IND (Investigational New Drug) and IDE (Investigational Device Exemption) filings submitted to the US FDA referencing or incorporating Miltenyi Biotec technologies, including reagents, instruments, and processing platforms for cell and gene therapy development.
Scalable by design
Built for scalability from the start, our manufacturing platforms support cell therapy production as demand grows – on your terms. Standardized, aligned workflows across the CliniMACS Prodigy® and MACSQuant® Analyzer enable technology transfer and reproducible performance across sites. Beyond the CliniMACS Cell Factory®, our flexible solutions support centralized and decentralized manufacturing without compromising quality or compliance.
Trusted worldwide
Our automated platforms are utilized and trusted by many users across the globe, supporting diverse cell and gene therapy modalities and indications across both centralized and decentralized manufacturing settings, from early clinical development through commercial-scale production.
These capabilities are realized through our advanced CGT platforms - the CliniMACS Prodigy and MACSQuant 16 Analyzer - designed to support you across critical applications.
You have previously chosen International as your location.
What do you want to do?